Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.
Recent Posts
- Does it still make sense to wait to claim Social Security retirement benefits? Here’s what experts say
- Commerce Secretary Lutnick says one trade deal is done, but waiting on approval from unnamed country’s leaders
- This is what typically happens to stocks after periods of high volatility
- Key money moves ahead of National College Decision Day: ‘It’s not just about the dream school … it’s also about the cost’
- UK announces draft rules for crypto industry, touts greater collaboration with U.S.